C. Wallis (London, United Kingdom), L. Garcia Marcos (Cartagena, Spain)
Prevalence of subnormal adrenal responses to low dose synthetic ACTH (synacthen) in children receiving ≥ 500 mcg daily of the inhaled steroid fluticasone propionate (FP)
E. Jardine, E. McNeil, P. Galloway, S. Beaton, M. Donaldson, J. Y. Paton (Glasgow, United Kingdom)
|  |
No-effect doses for effects on growth velocity (GV) in children receiving corticosteroids (CS)
P. T. Daley-Yates, S. D. Pyke, D. H. Richards (Greenford, United Kingdom)
| |
Aerodynamic precision of an inhalative medical device
R. Greguletz, R. P. Fuchs, B. Fyrnys (Frankfurt, Germany)
| |
Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler®
M. Everard, S. Ellis, S. Das (Sheffield, St Albans, United Kingdom)
| |
Aerosol delivery to young children: the relative importance of the facemask
J. E. Esposito-Festen, B. Ates, F. J. M. van Vliet, W. C. J. Hop, H. A. W. M. Tiddens (Rotterdam, The Netherlands)
| |
Use of exhaled nitric oxide (eNO) as a marker for anti-inflammatory dose-response of beclomethasone extrafine aerosol (Q) dosed once daily (50-100μg) in children with exercise-induced (EI) asthma
R. Pedersen, L. Agertoft, S. Pedersen (Kolding, Denmark)
| |
Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma
A. Emeryk, T. Bracamonte, U. Schauer, S. Balsara, R. Athisegaran (Lublin, Poland; Madrid, Spain; Bochum, Germany; Greenford, United Kingdom)
| |
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
U. Schauer, T. Bracamonte, A. Emeryk, S. Balsara, R. Athisegaran (Bochum, Germany; Madrid, Spain; Lublin, Poland; Greenford, United Kingdom)
| |
Comparison of long acting β 2-agonist inhalers for treatment of exercise-induced bronchoconstriction (EIB)
K. Gunawardena, P. Palmer, S. Das, A. Hewitt (Stoke Poges, St Albans, United Kingdom)
| |
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2agonists (LABA) + inhaled corticosteroids (ICS)
P. McCarthy, L. Rice, C. A. Blair (Uxbridge, United Kingdom)
| |
Retrospective study of GINA influence on long-term outcomes of bronchial asthma (CA) treatment in children
N. A. Mokina, N. A. Geppe (Samara, Moscow, Russia)
| |
For how long should beclomethasone be used so as to induce symptom control in asthma?
P. Camargos, C. Ibiapina, L. Lasmar, E. Goulart (Belo Horizonte, Brazil)
| |
Efficiency of the modern combined drugs in complex treatment of the asthmatic children
J. G. Levina, L. S. Namazova (Moscow, Russia)
| |
Salivary cortisol: reference values to study the assessing adrenal function in healthy children under three years old
G. F. Ferrari, M. L. Silva, M. C. Mallozi (Botucatu, Santo Andre, Brazil)
| |
Interventions to improve the adherence to controller therapy in asthmatic children
C. Gheonea, D. Bulucea, S. N. Dinescu, D. Butulescu (Craiova, Targu Jiu, Romania)
| |
Devices training program on inhaled therapy for childhood asthma
L. Mastrangelo, J. Avilan (Caracas, Venezuela)
| |
Paracetamol use in relation to asthma, hayfever, eczema and their current symptoms
E. G. Vlaski, L. M. Seckova, K. B. Stavric, R. D. Isjanovska, M. S. Kimovska (Skopje, Macedonia)
| |
The epidemiology of asthma (A) in schoolchildren in Northwest Yugoslavia (NWYU)
E. Panic, I. Panic (Sombor, Yugoslavia)
| |